Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (201-210 of 315) with videos related to

Pageof 32
Sort By:
American Journal of Clinical Dermatology|March 3, 2021
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical TrialElaine C Siegfried, Thomas Bieber, Eric L Simpson, et al.
The British Journal of Dermatology|December 20, 2023
How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users' guideKim S Thomas, Laura Howells, Yael A Leshem, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|August 7, 2024
TikTok Misinformation on the Role of Diet in Atopic Dermatitis ManagementKyra Diehl, Cara Barber, Eric L Simpson, et al.
Dermatology and Therapy|December 13, 2021
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term TreatmentApril Armstrong, Andrew Blauvelt, Eric L Simpson, et al.
American Journal of Clinical Dermatology|May 22, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE TrialEric L Simpson, Jonathan I Silverberg, Jacob P Thyssen, et al.
The Journal of Allergy and Clinical Immunology|December 17, 2013
Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitisMark K Slifka, Donald Y M Leung, Erika Hammarlund, et al.
The New England Journal of Medicine|March 15, 2023
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Emma Guttman-Yassky, Diamant Thaçi, et al.
Dermatology and Therapy|August 24, 2023
History of S. aureus Skin Infection Significantly Associates with History of Eczema Herpeticum in Patients with Atopic DermatitisMary C Moran, Alanna Klose, Takeshi Yoshida, et al.
JAMA Dermatology|January 11, 2023
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)Eric L Simpson, Melinda Gooderham, Andreas Wollenberg, et al.
Acta Dermato-Venereologica|March 22, 2019
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation AnalysisEric L Simpson, Gil Yosipovitch, Andrew G Bushmakin, et al.
Pageof 32

Showing results (201-210 of 315) with videos related to

Sort By:
Pageof 32
American Journal of Clinical Dermatology|March 3, 2021
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical TrialElaine C Siegfried, Thomas Bieber, Eric L Simpson, et al.
The British Journal of Dermatology|December 20, 2023
How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users' guideKim S Thomas, Laura Howells, Yael A Leshem, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|August 7, 2024
TikTok Misinformation on the Role of Diet in Atopic Dermatitis ManagementKyra Diehl, Cara Barber, Eric L Simpson, et al.
Dermatology and Therapy|December 13, 2021
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term TreatmentApril Armstrong, Andrew Blauvelt, Eric L Simpson, et al.
American Journal of Clinical Dermatology|May 22, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE TrialEric L Simpson, Jonathan I Silverberg, Jacob P Thyssen, et al.
The Journal of Allergy and Clinical Immunology|December 17, 2013
Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitisMark K Slifka, Donald Y M Leung, Erika Hammarlund, et al.
The New England Journal of Medicine|March 15, 2023
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Emma Guttman-Yassky, Diamant Thaçi, et al.
Dermatology and Therapy|August 24, 2023
History of S. aureus Skin Infection Significantly Associates with History of Eczema Herpeticum in Patients with Atopic DermatitisMary C Moran, Alanna Klose, Takeshi Yoshida, et al.
JAMA Dermatology|January 11, 2023
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)Eric L Simpson, Melinda Gooderham, Andreas Wollenberg, et al.
Acta Dermato-Venereologica|March 22, 2019
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation AnalysisEric L Simpson, Gil Yosipovitch, Andrew G Bushmakin, et al.
Pageof 32